RECURSION PHARMACEUTICALS, INC. (RXRX) is a publicly traded company in the Unknown sector. Across all available filings, 21 corporate insiders have executed 1015 transactions totaling $125.8M, demonstrating a bullish sentiment with $3.6M in net insider flow. The most recent transaction on Feb 19, 2026 involved a transaction of 40,000 shares valued at $0.
No significant insider buying has been recorded for RXRX in the recent period.
No significant insider selling has been recorded for RXRX in the recent period.
Based on recent SEC filings, insider sentiment for RXRX is bullish with an Insider Alignment Score of 51/100 and a net flow of $3.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at RECURSION PHARMACEUTICALS, INC. (RXRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 21 insiders are actively trading RXRX stock, having executed 1015 transactions in the past 90 days. The most active insider is Diversified Global Holding Pjsc Mamoura (Executive), who has made 24 transactions totaling $60.0M.
Get notified when executives and directors at RXRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Gibson Christopher | Executive | Conversion | 40,000 | $N/A | $0 | |
| Feb 19, 2026 | Gibson Christopher | Executive | Sale | 40,000 | $3.46 | $138.4K | |
| Feb 19, 2026 | Gibson Christopher | Executive | Conversion | 40,000 | $N/A | $0 | |
| Feb 18, 2026 | R. Taylor Ben | Chief Financial Officer | Sale | 13,426 | $3.08 | $41.4K | C-Suite |
| Feb 17, 2026 | Khan Najat | Executive | Payment | 14,280 | $3.49 | $49.8K | |
| Feb 17, 2026 | R. Taylor Ben | Chief Financial Officer | Payment | 11,908 | $3.49 | $41.6K | C-Suite |
| Feb 17, 2026 | Gibson Christopher | Executive | Payment | 27,265 | $3.49 | $95.2K | |
| Feb 17, 2026 | Hallett David | Chief Scientific Officer | Payment | 11,908 | $3.49 | $41.6K | |
| Feb 6, 2026 | Gibson Christopher | Executive | Payment | 10,364 | $3.56 | $36.9K | |
| Feb 6, 2026 | Gibson Christopher | Executive | Award | 30,346 | $N/A | $0 | |
| Feb 4, 2026 | Gibson Christopher | Executive | Conversion | 40,000 | $N/A | $0 | |
| Feb 4, 2026 | Gibson Christopher | Executive | Sale | 40,000 | $4.12 | $164.8K | |
| Feb 4, 2026 | Gibson Christopher | Executive | Conversion | 40,000 | $N/A | $0 | |
| Feb 3, 2026 | Borgeson Blake | Executive | Sale | 220,000 | $4.20 | $924.0K | Large |
| Jan 20, 2026 | Gibson Christopher | Executive | Conversion | 40,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 29 | $64.7M | 40.1% |
Sale(S) | 380 | $61.1M | 37.9% |
Award(A) | 120 | $25.0M | 15.5% |
Exercise(M) | 121 | $7.0M | 4.4% |
Payment(F) | 68 | $3.4M | 2.1% |
Conversion(C) | 205 | $0 | 0.0% |
Gift(G) | 55 | $0 | 0.0% |
Other(J) | 37 | $0 | 0.0% |
Insider activity at RECURSION PHARMACEUTICALS, INC. shows mixed signals across all time. While $64.7M in purchases indicates some executive confidence,$61.1M in sales balances the picture, resulting in a modest net flow of $3.6M.21 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Diversified Global Holding Pjsc Mamoura, has transacted $60.0M during this period.